Available Eye Drops for Allergic Conjunctivitis
For adults with allergic conjunctivitis, start with topical antihistamine/mast-cell stabilizer combination drops (such as olopatadine, ketotifen, or bilastine), which provide both immediate relief and prevention of symptoms. 1
First-Line Topical Agents
The primary treatment options include:
Dual-action antihistamine/mast-cell stabilizers: These are the preferred initial therapy because they address both acute symptoms and chronic disease through combined mechanisms 1. Specific agents include:
- Olopatadine 0.1% (twice daily) or 0.2% (once daily) - demonstrates superior efficacy with minimal discomfort on instillation 2
- Ketotifen 0.025% - effective antihistamine with proven efficacy 3
- Bilastine 0.6% preservative-free - newer once-daily option with 16-hour duration of action, superior bioadhesion, and excellent tolerability 3, 4
- Azelastine, epinastine (other available options)
Pure mast-cell stabilizers: Can be used for either acute or chronic disease, though they work more slowly than antihistamines 1
Adjunctive Therapies
Add these to your regimen for enhanced symptom control:
Preservative-free artificial tears (cooled): Use concomitantly to dilute allergens and inflammatory mediators while alleviating coexisting tear deficiency 1. This is particularly important since oral antihistamines may worsen dry eye.
Cool compresses: Simple environmental modification that provides symptomatic relief 1
Second-Line Options for Inadequate Control
If symptoms persist despite antihistamine/mast-cell stabilizers:
Short-course topical corticosteroids (1-2 weeks): Use low side-effect profile steroids for breakthrough symptoms 1. Important caveat: Monitor intraocular pressure and perform periodic pupillary dilation to screen for glaucoma and cataracts if using chronically 1.
Topical cyclosporine 0.05% or 0.1%: For severe cases or chronic disease. The 0.1% formulation is FDA-approved specifically for vernal keratoconjunctivitis in both children and adults 1. Use at least four times daily for effectiveness.
Topical tacrolimus: Available as 0.03% or 0.1% ointment (off-label for ophthalmic use), particularly useful for eyelid involvement in atopic disease 1
Key Clinical Considerations
Preservative-free formulations are superior when available, as they avoid cytotoxicity and promote better corneal wound healing compared to preserved formulations 5. Bilastine 0.6% with hyaluronic acid specifically enhances corneal hydration and retention 5.
Avoid oral antihistamines as monotherapy for ocular symptoms, as they may induce or worsen dry eye syndrome and impair the tear film's protective barrier 1.
Common pitfall: Patients with allergic conjunctivitis and atopic disease are at risk for keratoconus—adequate allergy control and preventing eye rubbing are critical to decrease ectasia progression 1.